Dan Aridor

AEBi was established in the year 2000, and has been managed since then based on the idea that the ability to manipulate and design peptides has vastly superior advantages to many, if not any, existing and trajectory technologies of drug development. This idea is valid today as well. The basic idea is that we do not require a natural lead or a sequence (usually coming from the academia or other research) which are either not strong enough or not specific enough and difficultto manipulate in order to create a drug. An artificial high complexity pool, representing a broad spectrum ofpossibilities, manipulated by our technology, will provide the best possible solution. Such asolutionwill not be hindered or blocked by natural interactions and will be very specific to the problem. AEBi, a development-stage biopharmaceutical company engaged in discovery and development of therapeutic peptides, has developed a combinatorial biology screening platform technology (IPprotected). The major advantage is that it can be used not only to find binders to known targets, but to select the best functional molecules among them. AEBi's platform is very flexible, exploiting combinatorial biology to discover new and better lead compounds to disease targets.